

JEW



PATENT
Attorney Docket No. 056291-5215

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: BRADBURY <i>et al.</i>)	Confirmation No.: 2826
)	
Application No.: 10/554,202)	Group Art Unit: 1624
)	
Filed: October 24, 2005)	Examiner: <i>Unassigned</i>
)	
For: 4-ANILINO-QUINAZOLINE DERIVATIVES)	
AS ANTIPROLIFERATIVE AGENTS)	Date: February 27, 2007

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Window, Mail Stop Amendment
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

INFORMATION DISCLOSURE STATEMENT

UNDER 37 C.F.R. § 1.97(b)

Citation of Technically Related U.S. Patent Applications

The Examiner's attention is directed to the following technically related U.S. patents or applications of Applicants' assignee:

Inventor	U.S. Serial No. Filing Date	U.S. Patent No. Issue Date	PCT Publication No. PCT Publication Date
Hennequin et al.	11/443,395 May 31, 2006		WO 03/040109 May 15, 2003
Hennequin <i>et al.</i>	11/443,208 May 31, 2006		WO 03/040108 May 15, 2003
Bradbury et al.	10/571,851 March 15, 2006		WO 2005/026151 March 24, 2005
Bradbury et al.	10/572,262 March 16, 2006		WO 2005/026152 March 24, 2005
Bradbury et al.	10/857,342 June 1, 2004		WO 2005/012290 November 4, 2004
Bradbury et al.	11/628,011 November 30, 2006		WO 2005/118572 December 15, 2005

Inventor	U.S. Serial No. Filing Date	U.S. Patent No. Issue Date	PCT Publication No. PCT Publication Date
Bradbury <i>et al.</i>	10/578,663 May 9, 2006		WO 2005/051923 June 9, 2005

A copy of the specification and claims for each application, in the form of the published PCT application from which such application was filed is being filed herewith. Consideration of each listed application is earnestly solicited

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants request the Examiner to consider this Information Disclosure Statement and the documents listed on the attached Form PTO-1449. To the best of the undersigned's knowledge, this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application. Accordingly, Applicants do not believe a fee is due for filing this Information Disclosure Statement.

With the exception of U.S. Patents, copies of the listed documents are attached. Applicants respectfully request that the Examiner initial and return the Form PTO-1449, indicating that the information has been considered and made of record herein.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." Applicants reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a


CONSTRUCTIVE PETITION FOR EXTENSION OF TIME in accordance with 37 C.F.R.

§1.136(a)(3).

Date: February 27, 2007
Morgan Lewis & Bockius LLP
Customer No. 09629
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Tel. No.: 202-739-3000

By:

Respectfully Submitted,
Morgan Lewis & Bockius LLP



Donald J. Bird
Registration No. 25,323
Tel. No.: (202) 739-5320
Fax No.: (202) 739-3001

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		Attorney Docket No. 056291-5215		Application No. 10/554,202			
		Applicants: BRADBURY et al.					
		Filing Date: October 24, 2005		Group Art Unit: 1624			
U.S. PATENT DOCUMENTS							
Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date	
	1.	US 4,322,420	March 30, 1982	Kobayashi et al.	514	266.4	September 11, 1979
	2.	US 4,640,920	February 3, 1987	Boyle et al.	514	248	June 13, 1985
	3.	US 5,405,843	April 11, 1995	Fukazawa et al.	514	183	September 9, 1993
	4.	US 5,721,237	February 24, 1998	Myers et al.	514	266.1	June 6, 1995
	5.	US 5,747,498	May 5, 1998	Schnur et al.	514	266.4	May 28, 1996
	6.	US 5,929,080	July 27, 1999	Frost	514	266.4	April 21, 1998
	7.	US 5,962,458	October 5, 1999	Lohmann et al.	514	266.21	December 17, 1996
	8.	US 6,004,967	December 21, 1999	McMahon et al.	514	266.4	September 11, 1997
	9.	US 6,046,206	April 4, 2000	Pamukcu et al.	514	266.21	April 30, 1997
	10.	US 6,117,433	September 12, 2000	Edens et al.	424	400	April 28, 1998
	11.	US 6,313,130	November 6, 2001	Uckun et al.	514	266.24	July 28, 2000
	12.	US 6,326,373	December 4, 2001	Uckun et al.	514	266.1	October 16, 2000
	13.	US 6,384,223	May 7, 2002	Gletsos	544	293	May 4, 2000
FOREIGN PATENT DOCUMENTS							
		Document No.	Date	Country	Class	Sub-Class	Translation
	14.	EP 0 326 330	July 24, 2002	EPA			
	15.	EP 0 520 722	December 27, 1996	EPA			
	16.	EP 0 566 226	November 8, 1995	EPA			
	17.	EP 0 602 851	October 9, 1996	EPA			
	18.	EP 0 787 722	August 6, 1997	EPA			
	19.	EP 0 837 063	April 22, 1998	EPA			
	20.	GB 2,295,387	May 29, 1996	United Kingdom			
	21.	JP-08-003144	January 17, 1996	Japan			Abstract
	22.	JP-11-189586	July 13, 1999	Japan			Abstract
	23.	WO 92/20642	November 26, 1992	WIPO			
	24.	WO 93/08170	April 29, 1993	WIPO			
	25.	WO 93/17682	September 16, 1993	WIPO			
	26.	WO 95/15758	June 15, 1995	WIPO			
	27.	WO 96/09294	March 28, 1996	WIPO			
	28.	WO 96/15118	May 23, 1996	WIPO			
	29.	WO 96/16960	June 6, 1996	WIPO			
	30.	WO 96/30347	October 3, 1996	WIPO			
	31.	WO 96/33977	October 31, 1996	WIPO			
	32.	WO 96/33978	October 31, 1996	WIPO			
	33.	WO 96/33979	October 31, 1996	WIPO			
	34.	WO 96/33980	October 31, 1996	WIPO			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
Examiner				Date Considered			
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Attorney Docket No.
056291-5215Application No.
10/554,202Applicants: **BRADBURY et al.**PTO Form 1449
February 27, 2007Filing Date: **October 24, 2005**Group Art Unit: **1624****U.S. PATENT DOCUMENTS**

Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date

FOREIGN PATENT DOCUMENTS

	Document No.	Date	Country	Class	Sub-Class	Translation
35.	WO 96/33981	October 31, 1996	WIPO			
36.	WO 96/39145	December 12, 1996	WIPO			
37.	WO 97/03069	January 30, 1997	WIPO			
38.	WO 97/11692	April 3, 1997	WIPO			
39.	WO 97/13771	April 17, 1997	WIPO			
40.	WO 97/22596	June 26, 1997	WIPO			
41.	WO 97/30034	August 21, 1997	WIPO			
42.	WO 97/30035	August 21, 1997	WIPO			
43.	WO 97/30044	August 21, 1997	WIPO			
44.	WO 97/38983	October 23, 1997	WIPO			
45.	WO 97/38994	October 23, 1997	WIPO			
46.	WO 98/02434	January 22, 1998	WIPO			
47.	WO 98/02437	January 22, 1998	WIPO			
48.	WO 98/02438	January 22, 1998	WIPO			
49.	WO 98/13354	April 2, 1998	WIPO			
50.	WO 98/38984	September 11, 1998	WIPO			
51.	WO 98/50038	November 12, 1998	WIPO			
52.	WO 98/50370	November 12, 1998	WIPO			
53.	WO 99/09016	February 25, 1999	WIPO			
54.	WO 99/24037	May 20, 1999	WIPO			
55.	WO 99/35132	July 15, 1999	WIPO			
56.	WO 99/35146	July 15, 1999	WIPO			
57.	WO 99/61428	December 2, 1999	WIPO			
58.	WO 00/00202	January 6, 2000	WIPO			
59.	WO 00/06555	February 10, 2000	WIPO			
60.	WO 00/10981	March 2, 2000	WIPO			
61.	WO 00/20402	April 13, 2000	WIPO			
62.	WO 00/44728	August 3, 2000	WIPO			
63.	WO 00/47212	August 17, 2000	WIPO			
64.	WO 00/51587	September 8, 2000	WIPO			
65.	WO 00/51991	September 8, 2000	WIPO			
66.	WO 00/55141	September 21, 2000	WIPO			
67.	WO 00/73260	December 7, 2000	WIPO			
68.	WO 01/12227	February 22, 2001	WIPO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) PTO Form 1449 February 27, 2007				Attorney Docket No. 056291-5215		Application No. 10/554,202	
				Applicants: BRADBURY et al.			
				Filing Date: October 24, 2005		Group Art Unit: 1624	

U.S. PATENT DOCUMENTS							
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date

FOREIGN PATENT DOCUMENTS							
		Document No.	Date	Country	Class	Sub-Class	Translation
	69.	WO 01/21594	March 29, 2001	WIPO			
	70.	WO 01/21595	March 29, 2001	WIPO			
	71.	WO 01/32632	May 10, 2001	WIPO			
	72.	WO 01/45641	June 28, 2001	WIPO			
	73.	WO 01/77085	October 18, 2001	WIPO			
	74.	WO 01/94341	December 13, 2001	WIPO			
	75.	WO 01/98277	December 27, 2001	WIPO			
	76.	WO 02/18372	March 7, 2002	WIPO			Abstract
	77.	WO 02/41882	May 30, 2002	WIPO			
	78.	WO 03/040108	May 15, 2003	WIPO			
	79.	WO 03/040109	May 15, 2003	WIPO			
	80.	WO 03/082290	October 9, 2003	WIPO			
	81.	WO 03/082831	October 9, 2003	WIPO			
	82.	WO 2004/006846	January 22, 2004	WIPO			
	83.	WO 2004/096226	November 11, 2004	WIPO			
	84.	WO 2005/012290	November 4, 2004	WIPO			
	85.	WO 2005/013998	February 17, 2005	WIPO			
	86.	WO 2005/026150	March 24, 2005	WIPO			
	87.	WO 2005/026151	March 24, 2005	WIPO			
	88.	WO 2005/026152	March 24, 2005	WIPO			
	89.	WO 2005/026156	March 24, 2005	WIPO			
	90.	WO 2005/026157	March 24, 2005	WIPO			
	91.	WO 2005/028469	March 31, 2005	WIPO			
	92.	WO 2005/028470	March 31, 2005	WIPO			
	93.	WO 2005/030757	April 7, 2005	WIPO			
	94.	WO 2005/030765	April 7, 2005	WIPO			
	95.	WO 2005/051923	June 9, 2005	WIPO			
	96.	WO 2005/075439	August 18, 2005	WIPO			
	97.	WO 2005/118572	December 15, 2005	WIPO			
	98.	WO 2006/008526	January 26, 2006	WIPO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)	
99.	Ballard et al. "5-Substituted 4-anilinoquinazolines as potent, selective and orally active inhibitors of erbB2 receptor tyrosine kinase" Bioorg Med Chem Lett. 15(19):4226-4229 (2005)
100.	Ballard et al. "Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocket" Bioorg Med Chem Lett. 16(6):1633-1637 (2006)

Examiner	Date Considered
----------	-----------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) PTO Form 1449 February 27, 2007				Attorney Docket No. 056291-5215		Application No. 10/554,202	
				Applicants: BRADBURY et al.			
				Filing Date: October 24, 2005		Group Art Unit: 1624	
U.S. PATENT DOCUMENTS							
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date
FOREIGN PATENT DOCUMENTS							
		Document No.	Date	Country	Class	Sub-Class	Translation
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
	101.	Ballard et al. "Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics" <i>Bioorg Med Chem Lett.</i> 16(18):4908-4912 (2006)					
	102.	Barker et al. "Studies leading to the identification of ZD1839 (Iressa TM): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer" <i>Bioorganic and Medicinal Chemistry Letters</i> 11(14):1911-1914 (2001)					
	103.	Bridges et al. "Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor" <i>J. Med. Chem.</i> 39(1):267-276 (1996)					
	104.	Denny et al. "Structure-activity relationships for 4-anilinoquinazolines as potent inhibitors at the ATP binding site for the epidermal growth factor receptor in vitro" <i>Clinical and Experimental Pharmacology and Physiology</i> 23:424-427 (1996)					
	105.	Harris et al. "Facile synthesis of 7-amino anilinoquinazolines via direct amination of the quinazoline core" <i>Tetrahedron letters</i> 46(43): 7381-7384 (2005)					
	106.	Harris et al. "Selective alkylation of a 6,7-dihydroxyquinazoline" <i>Tetrahedron letters</i> 46(45):7715-7719 (2005)					
	107.	Hennequin et al. "Novel 4-anilinoquinazolines with C-6 carbon-linked side chains: synthesis and structure-activity relationship of a series of potent, orally active, EGF receptor tyrosine kinase inhibitors" <i>Bioorg Med Chem Lett.</i> 16(10):2672-2676 (2006)					
	108.	Hennequin et al. "Novel 4-Anilinoquinazolines with C-7 Basic Side Chains: Design and Structure Activity Relationship of a Series of Potent, Orally Active, VEGF Receptor Tyrosine Kinase Inhibitors" <i>J. Med. Chem.</i> 45 (6):1300 -1312 (2002)					
	109.	Rewcastle et al. "Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor" <i>J. Med. Chem.</i> 38:3482-3487 (1995)					
	110.	Stamos et al. "Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor" <i>J. Biol. Chem.</i> 277(48):46265-46272 (2002)					
	111.	Traxler et al. "Protein tyrosine kinase inhibitors in cancer treatment" <i>Exp. Opin. Ther. Patents</i> 7(6):571-588 (1997)					
	112.	Traxler et al. "Tyrosine kinase inhibitors in cancer treatment (Part II)" <i>Exp. Opin. Ther. Patents</i> 8(12):1599-1625 (1998)					
	113.	Tsou et al. "6-Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity" <i>J. Med. Chem.</i> 44:2719-2734 (2001)					
	114.	Vema et al. "Design of EGFR kinase inhibitors: a ligand-based approach and its confirmation with structure-based studies" <i>Bioorg Med Chem.</i> 11(21):4643-4653 (2003)					
Examiner				Date Considered			
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							